1. Home
  2. SEV vs BMEA Comparison

SEV vs BMEA Comparison

Compare SEV & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aptera Motors Corp.

SEV

Aptera Motors Corp.

HOLD

Current Price

$2.20

Market Cap

77.9M

Sector

Industrials

ML Signal

HOLD

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.26

Market Cap

91.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEV
BMEA
Founded
2019
2017
Country
United States
United States
Employees
46
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
77.9M
91.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SEV
BMEA
Price
$2.20
$1.26
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$9.83
AVG Volume (30 Days)
285.6K
628.6K
Earning Date
05-16-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.19
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$17,757.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.29
$0.87
52 Week High
$11.24
$2.99

Technical Indicators

Market Signals
Indicator
SEV
BMEA
Relative Strength Index (RSI) 57.28 48.75
Support Level $1.97 $1.21
Resistance Level $2.45 $1.44
Average True Range (ATR) 0.12 0.06
MACD 0.05 -0.00
Stochastic Oscillator 70.00 62.79

Price Performance

Historical Comparison
SEV
BMEA

About SEV Aptera Motors Corp.

Aptera Motors Corp engages in the development, production, and distribution of energy efficient solar-powered, battery-electric vehicles. The company has designed the Aptera vehicle to provide up to an estimated 40 miles per day by collecting energy from the sun and storing it in its proprietary battery pack. The company operates as a single reportable segment focused on the development of solar electric vehicles.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: